FRED G. WEISS

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

BLACKROCK CORPORATE HIGH YIELD FUND, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss - Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001.

BLACKROCK FLOATING RATE INCOME STRATEGIES FUND, INC.

Filing Date Source Excerpt
2006-06-15 Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001.

BLACKROCK MUNIASSETS FUND, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Watson Pharmaceutical Inc. (pharmaceutical company). Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. Each non-interested Board Member also receives an aggregate fee of $3,000 for each special in-person meeting attended, which is allocated equally among all the applicable FAM/MLIM-advised funds overseen by the Board Member. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000. The Fund reimburses each non-interested Board Member for his or her out-of-pocket expenses relating to attendance at Board, Audit Committee and any Nominating Committee meetings.

BLACKROCK MUNIVEST FUND II, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. Each non-interested Board Member also receives an aggregate fee of $3,000 for each special in-person meeting attended, which is allocated equally among all the applicable FAM/MLIM-advised funds overseen by the Board Member. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000. The Fund reimburses each non-interested Board Member for his or her out-of-pocket expenses relating to attendance at Board, Audit Committee and any Nominating Committee meetings.

BLACKROCK MUNIVEST FUND, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. Nominating Committee Members for Funds supervised by Board A include Fred G. Weiss. Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000.

BLACKROCK MUNIYIELD FUND, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios Nominating Committee Members for Funds supervised by Board A: Donald W. Burton, Jack F. O'Brien, David H. Walsh and Fred G.Weiss

BLACKROCK MUNIYIELD MICHIGAN QUALITY FUND, INC.

Filing Date Source Excerpt
2001-03-21 Fred G. Weiss 16450 Maddalena Place Delray Beach, Florida 33446, Age 59, Managing Director of FGW Associates; Member of the Audit and Nominating Committee; Aggregate Compensation $156,892.
2002-03-22 Fred G. Weiss (60) Director/Trustee. Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of BTG International PLC (a global technology commercialization company) since 2001; Director of the Michael J. Fox Foundation for Parkinson's Research.
2003-03-14 Fred G. Weiss (61) Director Director of each Fund since the year listed in Exhibit B Managing Director of FGW Associates since 1997; Vice President, Planning, Investment, and Development of Warner Lambert Co., from 1979 to 1997; Director of BTG International PLC (a global technology commercialization company) since 2001; Director of the Michael J. Fox Foundation for Parkinson's Research. 23 registered investment companies consisting of 35 portfolios Watson Pharmaceutical Inc. (pharmaceutical company) Audit Committee Report. The Board of Directors of each Fund has a standing Audit and Nominating Committee (the Committee), which consists of the Directors who are non-interested Directors of the Fund and who are independent as defined in the listing standards of the New York Stock Exchange (NYSE) and, with respect to S&P 500, the Nasdaq National Market System (Nasdaq). Currently, Messrs. Burton, Crum, and Weiss and Ms. Hodrick are members of the Committee of each Fund. The principal responsibilities of the Committee are the appointment, compensation and oversight of the Fund's independent accountants, including the resolution of disagreements regarding financial reporting between Fund management and such independent accountants. Compensation of Non-Interested Directors Name Aggregate Compensation from each Fund Fred G. Weiss $28,500 Pension or Retirement Benefits Accrued as Part of Fund Expense None Estimated Annual Benefits upon Retirement None Aggregate Compensation from Fund and Other MLIM/FAM-Advised Funds $208,917
2004-03-18 Fred G. Weiss (62) Director Director of each Fund since the year listed in Exhibit B Managing Director of FGW Associates since 1997; Vice President, Planning, Investment, and Development of Warner Lambert Co., from 1979 to 1997; Director of BTG International PLC (a global technology commercialization company) since 2001; Director of the Michael J. Fox Foundation for Parkinson’s Research. Each of the Director Nominees is a member of the Audit Committee and the Nominating Committee of each Fund. Set forth in the table below is information regarding compensation paid by each Fund to the non-interested Directors during each Fund’s most recently completed fiscal year. MY FL Weiss 5,250.
2005-03-22 Fred G. Weiss** (63) Director Director of each Fund since the year listed in Exhibit B. Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of BTG International PLC (a global technology commercialization company) since 2001; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000. Each non-interested Director Nominee is a member of each Fund's Audit Committee and Nominating Committee. Chairman of the Audit Committee of each Fund.
2006-03-22 Fred G. Weiss (64) - Director of each Fund since the year listed in Exhibit B. Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. Chairman of the Audit Committee of each Fund. Each non-interested Director Nominee is a member of each Fund's Audit Committee and Nominating Committee. Set forth in the table below is information regarding the aggregate compensation paid by MLIM/FAM-advised funds to the non-interested Directors for the year ended December 31, 2005: Fred G. Weiss - $230,000.
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Chairman of the Audit Committee of each Fund. Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. Each non-interested Board Member also receives an aggregate fee of $3,000 for each special in-person meeting attended, which is allocated equally among all the applicable FAM/MLIM-advised funds overseen by the Board Member. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000. The Fund reimburses each non-interested Board Member for his or her out-of-pocket expenses relating to attendance at Board, Audit Committee and any Nominating Committee meetings.

BLACKROCK MUNIYIELD NEW YORK QUALITY FUND, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Watson Pharmaceutical Inc. (pharmaceutical company). Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. Each non-interested Board Member also receives an aggregate fee of $3,000 for each special in-person meeting attended, which is allocated equally among all the applicable FAM/MLIM-advised funds overseen by the Board Member. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000. The Fund reimburses each non-interested Board Member for his or her out-of-pocket expenses relating to attendance at Board, Audit Committee and any Nominating Committee meetings.

BLACKROCK MUNIYIELD PENNSYLVANIA QUALITY FUND

Filing Date Source Excerpt
2001-03-21 Fred G. Weiss 16450 Maddalena Place Delray Beach, Florida 33446, Age 59, Managing Director of FGW Associates; Member of the Audit and Nominating Committee; Aggregate Compensation Paid: $156,892.
2002-03-22 Fred G. Weiss (60) Director/Trustee Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of BTG International PLC since 2001; Director of the Michael J. Fox Foundation for Parkinson's Research
2003-03-14 Fred G. Weiss (61) Director Director of each Fund since the year listed in Exhibit B Managing Director of FGW Associates since 1997; Vice President, Planning, Investment, and Development of Warner Lambert Co., from 1979 to 1997; Director of BTG International PLC (a global technology commercialization company) since 2001; Director of the Michael J. Fox Foundation for Parkinson's Research. 23 registered investment companies consisting of 35 portfolios Watson Pharmaceutical Inc. (pharmaceutical company) The Board of Directors of each Fund has a standing Audit and Nominating Committee (the "Committee"), which consists of the Directors who are non-interested Directors of the Fund and who are "independent" as defined in the listing standards of the New York Stock Exchange ("NYSE") and, with respect to S&P 500, the Nasdaq National Market System ("Nasdaq"). Currently, Messrs. Burton, Crum, and Weiss and Ms. Hodrick are members of the Committee of each Fund. The principal responsibilities of the Committee are the appointment, compensation and oversight of the Fund's independent accountants, including the resolution of disagreements regarding financial reporting between Fund management and such independent accountants. Each Fund currently pays each non-interested Director a combined fee of $2,500 per year plus $250 per meeting attended, together with such Director's actual out-of-pocket expenses relating to attendance at meetings. Each Fund also pays each member of its Committee, which consists of all of the non-interested Directors of such Fund, a fee of $2,500 per year plus $250 per Committee meeting attended. The Chairman of each Fund's Committee receives an additional fee of $500 per year. Fred G. Weiss Aggregate Compensation from each Fund $28,500.
2004-03-18 Fred G. Weiss (62) Director Director of each Fund since the year listed in Exhibit B Managing Director of FGW Associates since 1997; Vice President, Planning, Investment, and Development of Warner Lambert Co., from 1979 to 1997; Director of BTG International PLC (a global technology commercialization company) since 2001; Director of the Michael J. Fox Foundation for Parkinson’s Research. Each of the Director Nominees is a member of the Audit Committee and the Nominating Committee of each Fund. Set forth in the table below is information regarding compensation paid by each Fund to the non-interested Directors during each Fund’s most recently completed fiscal year. MY FL: 5,250.
2005-03-22 Fred G. Weiss** (63) Director Director of each Fund since the year listed in Exhibit B. Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of BTG International PLC (a global technology commercialization company) since 2001; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000. Each non-interested Director Nominee is a member of each Fund's Audit Committee and Nominating Committee. Chairman of the Audit Committee of each Fund.
2006-03-22 Fred G. Weiss (64) - Director of each Fund since the year listed in Exhibit B. Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. Chairman of the Audit Committee of each Fund. Set forth in the table below is information regarding the aggregate compensation paid by MLIM/FAM-advised funds to the non-interested Directors for the year ended December 31, 2005: Fred G. Weiss - $230,000.
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Chairman of the Audit Committee of each Fund. Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. Each non-interested Board Member also receives an aggregate fee of $3,000 for each special in-person meeting attended, which is allocated equally among all the applicable FAM/MLIM-advised funds overseen by the Board Member. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000. The Fund reimburses each non-interested Board Member for his or her out-of-pocket expenses relating to attendance at Board, Audit Committee and any Nominating Committee meetings.

BLACKROCK MUNIYIELD QUALITY FUND III, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Watson Pharmaceutical Inc. (pharmaceutical company). Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. Each non-interested Board Member also receives an aggregate fee of $3,000 for each special in-person meeting attended, which is allocated equally among all the applicable FAM/MLIM-advised funds overseen by the Board Member. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000. The Fund reimburses each non-interested Board Member for his or her out-of-pocket expenses relating to attendance at Board, Audit Committee and any Nominating Committee meetings.

BLACKROCK MUNIYIELD QUALITY FUND II, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Muni Intermediate and Muni New York Intermediate each pay each non-interested Board Member a combined fee for services on the Board and the Audit Committee of $3,000 per year, $250 per in person Board meeting attended and $250 per in person Audit Committee meeting attended. Each non-interested Board Member also receives an aggregate fee of $3,000 for each special in-person meeting attended, which is allocated equally among all the applicable FAM/MLIM-advised funds overseen by the Board Member. The Fund pays the Chairman of the Audit Committee an additional annual fee of $1,000. The Fund reimburses each non-interested Board Member for his or her out-of-pocket expenses relating to attendance at Board, Audit Committee and any Nominating Committee meetings.

BLACKROCK MUNIYIELD QUALITY FUND, INC.

Filing Date Source Excerpt
2006-06-15 Fred G. Weiss (64) Board Member Managing Director of FGW Associates since 1997; Vice President, Planning Investment and Development of Warner Lambert Co. from 1979 to 1997; Director of the Michael J. Fox Foundation for Parkinson's Research since 2000; Director of BTG International PLC (a global technology commercialization company) since 2001. 23 registered investment companies consisting of 42 portfolios. Chairman of the Audit Committee of each Fund. Each Fund supervised by Board A pays each Independent Board Member a combined fee for service on the Board and the Audit Committee. Annual fee $3,000, per meeting fee $250, Chairman of the Audit Committee additional annual fee $1,000.

Data sourced from SEC filings. Last updated: 2026-02-03